Abstract: The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by HIV-1 virus infections. In particular, the oligosaccharides globotriose and lactose may be used alone or in combination to competitively inhibit the formation of the viral fusion complex that occurs upon infection.

Abstract: The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by infection with Shiga toxin (ST) or Shiga-like toxin (SHL). In particular, the trisaccharide globotriose (i.e., galactose &agr;1,4 galactose &bgr;1,4 glucose) may be used to competitively inhibit binding of the toxins to their cellular targets.

Abstract: The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by infection with Shiga toxin (ST) or Shiga-like toxin (SHL). In particular, the trisaccharide globotriose (i.e., galactose &agr;1,4 galactose &bgr;1,4 glucose) may be used to competitively inhibit binding of the toxins to their cellular targets.

Abstract: The subject intention relates to compositions containing at least one fucose residue in an &agr;1-2 linkage and uses thereof. In particular, such compositions can be used in the treatment and prevention of gastrointestinal infections caused by, for example, Escherichia coil and Vibrio cholerae. The subject invention also encompasses methods of screening for the above compositions. Additionally, the subject invention includes vaccines.

Abstract: The subject invention relates to methods of producing non-human transgenic mammals which produce various oligosaccharides and glycoconjugates in their milk. Additionally, the subject invention relates to the mammals themselves, the milk which they produce, compositions comprising the milk, fractions of the milk, and the purified oligosaccharides, as well as glyconjugates, present in the milk.

Abstract: A nutritional formulation containing at least one of the following oligosaccharides: from about 400 to about 3500 mg/L of 3-fucosyllactose; from about 200 to about 2200 mg/L of lacto-N-fucopentaose III; from about 100 to about 1500 mg/L of lacto-N-fucopentaose II; from about 100 to about 2500 mg/L of difucosyllactose; from about 500 to about 4500 mg/L of 2' fucosyllactose; from about 250 to about 3300 mg/L of lacto-N-fucopentaose I; from about 100 to about 900 mg/L of Lacto-N-neoTetraose; from about 50 to about 2300 mg/L of lacto-N-fucopentaose V; or from about 300 to about 2800 mg/L of lacto-N-tetraose.

Abstract: A nutritional formulation containing an effective amount of Lacto-N-neoTetraose to simulate the growth and/or metabolic activity of Bifidobacterium is provided. A process of inhibiting bacterial infections caused by Bacteroides, Clostridium, and E. coli including the step of feeding the nutritional composition to a subject is also provided.

Abstract: A nutritional formulation containing at least one of the following oligosaccharides: from about 400 to about 3500 mg/L of 3-fucosyllactose; from about 200 to about 2200 mg/L of lacto-N-fucopentaose III; from about 100 to about 1500 mg/L of lacto-N-fucopentaose II; from about 100 to about 2500 mg/L of difucosyllactose; from about 500 to about 4500 mg/L of 2' fucosyllactose; from about 250 to about 3300 mg/L of lacto-N-fucopentaose I; from about 100 to about 900 mg/L of Lacto-N-neoTetraose; from about 50 to about 2300 mg/L of lacto-N-fucopentaose V; or from about 300 to about 2800 mg/L of lacto-N-tetraose.

Abstract: The present invention relates to a process for synthesizing oligosaccharides. The process involves contacting an acceptor moiety with unpurified sugar-nucleotides and/or unpurified glycosyltransferase to synthesize oligosaccharides.

Abstract: A nutritional formulation containing an effective amount of Lacto-N-neoTetraose to simulate the growth and/or metabolic activity of Bifidobacterium is provided. A process of inhibiting bacterial infections including the step of feeding the nutritional composition to a subject is also provided.

Abstract: A method of preventing or treating infection by human rotavirus by administering an enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.